Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811721 | 1.00 | HSD11B1 (0.42) | HSD11B1MAPTCHRM4ALDH1A1LMNA | |
| SCHEMBL6808203 | 0.88 | MAPT (0.45) | HSD11B1MAPTCHRM4ALDH1A1LMNA | |
| SCHEMBL6808198 | 0.88 | MAPT (0.45) | HSD11B1MAPTCHRM4ALDH1A1LMNA | |
| SCHEMBL6808586 | 0.75 | ALDH1A1 (0.44) | HSD11B1MAPTALDH1A1LMNA | |
| SCHEMBL6808590 | 0.75 | ALDH1A1 (0.44) | HSD11B1MAPTALDH1A1LMNA | |
| SCHEMBL4573282 | 0.74 | HSD11B1 (0.45) | HSD11B1CHRM4 | |
| SCHEMBL9959713 | 0.73 | NOTUM (0.54) | MAPTCHRM4ALDH1A1LMNASMO | |
| SCHEMBL28094549 | 0.72 | MAPT (0.53) | MAPTCHRM4ALDH1A1LMNA | |
| SCHEMBL20874064 | 0.72 | MAPT (0.53) | MAPTCHRM4ALDH1A1LMNA | |
| SCHEMBL23291446 | 0.71 | HSD11B1 (0.47) | HSD11B1MAPTCHRM4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HSD11B1 63/4885MAPT 2401/4885CHRM4 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.